{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T06:33:59Z","timestamp":1762065239305,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508del mutation in the transmembrane conductance regulator of the cystic fibrosis gene. Among the adverse events of elexacaftor, tezacaftor and ivacaftor, the cutaneous ones have been rarely reported, mainly dealing with urticarial-like rashes. On this topic, we report two cases of Malassezia folliculitis following triple therapy administration in two young females. In the first patient, a papulopustular rush appeared before the folliculitis while in the second patient it was not preceded by other skin manifestations. The diagnosis was confirmed both by dermoscopy and histology. The prompt response to systemic antimycotic drugs provided further evidence for the causative role of Malassezia, requiring no discontinuation of cystic fibrosis therapy. We could hypothesize that the triple regimen treatment may induce changes in the skin microbiome, potentially able to favor colonization and proliferation of Malassezia species. Physicians should be aware of such associations to allow prompt diagnosis and early interventions, avoiding useless drug removal.<\/jats:p>","DOI":"10.3390\/medicina58091204","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:19:01Z","timestamp":1662077941000},"page":"1204","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-9468","authenticated-orcid":false,"given":"Federica","family":"Li Pomi","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-6246","authenticated-orcid":false,"given":"Luca","family":"Di Bartolomeo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5145","authenticated-orcid":false,"given":"Mario","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lentini","sequence":"additional","affiliation":[{"name":"Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Cristadoro","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Lucanto","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Costa","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-8441","authenticated-orcid":false,"given":"Francesco","family":"Borgia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic Fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic Fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic Fibrosis","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019Hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation: A Double-Blind, Randomised, Phase 3 Trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR Modulator Drug Desensitization: Preserving the Hope of Long Term Improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/postgradmedj-2020-139264","article-title":"\u2018Triple Therapy\u2019 (Elexacaftor, Tezacaftor, Ivacaftor) Skin Rash in Patients with Cystic Fibrosis","volume":"98","author":"Hu","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sosinski, L.M., H, C.M., Neugebauer, K.A., Ghuneim, L.-A.J., Guzior, D.V., Castillo-Bahena, A., Mielke, J., Thomas, R., McClelland, M., and Conrad, D. (2021). A Restructuring of Microbiome Niche Space Is Associated with Elexacaftor-Tezacaftor-Ivacaftor Therapy in the Cystic Fibrosis Lung. J. Cyst. Fibros.","DOI":"10.1016\/j.jcf.2021.11.003"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdcr.2021.10.018","article-title":"Urticaria Multiforme-like Eruption Due to a Novel Agent Elexacaftor\/Tezacaftor\/Ivacaftor in a Pediatric Patient with Cystic Fibrosis","volume":"18","author":"Goldberg","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e247042","DOI":"10.1136\/bcr-2021-247042","article-title":"Elexacaftor, Tezacaftor and Ivacaftor: A Case of Severe Rash and Approach to Desensitisation","volume":"15","author":"Cheng","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Stashower, J., Carr, P., Miller, V., and Zlotoff, B. (2021). Novel Reaction to New Cystic Fibrosis Medication Trikafta. Clin. Case Rep., 9.","DOI":"10.1002\/ccr3.4116"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.anai.2021.08.010","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor Outpatient Desensitization","volume":"128","author":"Balijepally","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_16","first-page":"467","article-title":"If At First You Don\u2019t Succeed, Trikafta Again","volume":"27","author":"Loyd","year":"2022","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D3271156096","article-title":"An Acneiform Eruption Associated with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment","volume":"27","author":"Breneman","year":"2022","journal-title":"Dermatol. Online J."},{"key":"ref_18","first-page":"463","article-title":"Rechallenge of Elexacaftor\/Tezacaftor\/Ivacaftor After Skin Rash in Two Pediatric Patients","volume":"27","author":"Diseroad","year":"2022","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_19","first-page":"37","article-title":"Malassezia (Pityrosporum) Folliculitis","volume":"7","author":"Rubenstein","year":"2014","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ijd.13116","article-title":"Malassezia Species in Healthy Skin and in Dermatological Conditions","volume":"55","author":"Prohic","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jdv.16253","article-title":"Critical Synthesis of Available Data in Malassezia Folliculitis and a Systematic Review of Treatments","volume":"34","author":"Vlachos","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.5021\/ad.2014.26.5.598","article-title":"Comparison between Malassezia Folliculitis and Non- Malassezia Folliculitis","volume":"26","author":"Song","year":"2014","journal-title":"Ann. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fcimb.2020.00112","article-title":"Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment","volume":"10","author":"Saunte","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/9\/1204\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:09Z","timestamp":1760142129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/9\/1204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["medicina58091204"],"URL":"https:\/\/doi.org\/10.3390\/medicina58091204","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}